Join us for lunch.

Guest Speaker: Dr Michael Thurn Managing Director & CEO PharmAust

Topic: Are Biotechs Focusing on Treatments for Rare Diseases Good Investments?

Dr Michael Thurn brings broad experience in drug discovery, development, regulation and commercialisation, acquired through leadership roles in research organisations and industry, including early stage, fast-growing, private and publicly listed biotechnology companies. His previous responsibilities have included leading a variety of US Food and Drug Administration (FDA) Investigational New Drug applications across a range of therapeutic areas and the evaluation of drugs and vaccines for registration in Australia as a part of the Drug Safety Evaluation Branch of the Therapeutics Goods Administration (TGA).

Dr Thurn has also been responsible for the execution of Phase 1 and 2 clinical trials and business development activities across animal and human health products. He possesses strong entrepreneurial, leadership and management skills that have seen him achieve outstanding results over a 25-year career in the biotechnology industry, including co-founding MARP Therapeutics and roles with Botanix Pharmaceuticals (ASX:BOT), Mimetica, Spinifex Pharmaceuticals, Cytopia, Xenome and Novogen. During this time, Dr Thurn has gained Australian and US capital markets exposure and has successfully accessed funding through private and public channels, partnerships, and non-dilutive means.

$85 per head. Buy tickets at collinsclub.com.au

Date: September 13th 2024
Time: 12:30pm
Where: The Kelvin Club

BOOK HERE